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Summary
 
In mature B lymphocytes, the zinc finger transcription factor early growth response 1 (Egr-1) is
one of the many immediate-early genes induced upon B cell antigen receptor engagement.
However, its role during earlier stages of lymphopoiesis has remained unclear. By examining
bone marrow B cell subsets, we found Egr-1 transcripts in pro/pre-B and immature B lympho-
cytes, and Egr-1 protein in pro/pre-B–I cells cultivated on stroma cells in the presence of inter-
leukin (IL)-7. In recombinase-activating gene (RAG)-2–deficient mice overexpressing an Egr-1
transgene in the B lymphocyte lineage, pro/pre-B–I cells could differentiate past a develop-
mental block at the B220
 
low
 
 BP-1
 
2
 
 stage to the stage of B220
 
low
 
 BP-1
 
1
 
 pre-B–I cells, but not
further to the B220
 
low
 
 BP-1
 
1
 
 CD25
 
1
 
 stage of pre-B–II cells. Therefore, during early B lym-
phopoiesis progression from the B220
 
low
 
 BP-1
 
2
 
 IL-2R
 
2
 
 pro/pre-B–I stage to the B220
 
low
 
 BP-
1
 
1
 
 IL-2R
 
1
 
 pre-B–II stage seems to occur in at least two distinct steps, and the first step to the
stage of B220
 
low
 
 BP-1
 
1
 
 pre-B–I cells can be promoted by the overexpression of Egr-1 alone.
Wild-type mice expressing an Egr-1 transgene had increased proportions of mature immuno-
globulin (Ig)M
 
1
 
 B220
 
high
 
 and decreased proportions of immature IgM
 
1
 
 B220
 
low
 
 bone marrow
B cells. Since transgenic and control precursor B cells show comparable proliferation patterns,
overexpression of Egr-1 seems also to promote entry into the mature B cell stage. Analysis of
changes in the expression pattern of potential Egr-1 target genes revealed that Egr-1 enhances
the expression of the aminopeptidase BP-1/6C3 in pre-B and immature B cells and upregulates
expression of the orphan nuclear receptor nur77 in IgM
 
1
 
 B cells.
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A
 
ntigen binding to surface (s)Igs in B cells initiates a
signal cascade which in the context of secondary sig-
nals leads to proliferation and differentiation of mature rest-
ing B lymphocytes into plasma or memory cells. Changes
in the activity and expression of transcription factors trans-
late activating signals into the modulated expression pattern
of downstream genes. One of these transcription factors is
called early growth response 1 (Egr-1;
 
1
 
 also known as
Krox-24, NGFI-A, Tis-8, zif268, pAT225, or Z-225 [1–3]).
Egr-1 is induced very rapidly in many different cell types
and tissues, including fibroblasts (1), monocytes (4), lym-
phocytes (5, 6), kidney (7), neurons (3), and brain (8), in
response to a wide range of signals (1–3, 5, 9). In mature B
lymphocytes, transient Egr-1 expression is rapidly induced
upon stimulation by B cell antigen receptor (BCR) cross-
linking (5, 10), whereas signals resulting from Fc receptor
cross-linking inhibit induction (11, 12). Thus, the broad
spectrum of Egr-1 expression and the diverse modes of
Egr-1 induction suggest that Egr-1 functions as a transcrip-
tional regulator that links common biochemical signaling
pathways to the rapid modulation of downstream gene ex-
pression.
Mature peripheral B lymphocytes originate from bone
marrow precursor cells that are ordered according to their
phenotype, gene expression, Ig gene rearrangement, and
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; BrdU, bro-
modeoxyuridine; Egr-1, early growth response 1; EMSA, electrophoretic
mobility shift assay; ERK, extracellular signal–regulated kinase; RAG, re-
combinase-activating gene.
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proliferative and developmental potential into the pro-B,
pre-B, and immature B lymphocyte subsets (13–17). Tran-
scriptional regulation plays a critical role during B cell devel-
opment (for a review, see reference 18) as shown by gene
targeting of multiple transcription factors. Mutations in these
factors that obliterate their activity were shown to arrest B
lymphopoiesis at defined stages of maturation (19–29).
Little is known about the expression and function of
Egr-1 during early steps of B cell differentiation. Here we
report that Egr-1 expression can be detected already in pre-B
cells isolated from bone marrow and in fetal liver–derived
pre-B cell cultures. These results suggested that Egr-1
might also have a regulatory function in early stages of B
lymphopoiesis. However, mice deficient for Egr-1 fail to
show defects in lymphocyte or monocyte maturation, most
probably because the missing Egr-1 activity is masked by
other members of the Egr transcription factor family (30,
31). To bypass the complementing activity of Egr-2, Egr-3,
or Egr-4, we studied B lymphocyte differentiation in trans-
genic mice overexpressing Egr-1 in B cells in normal
and recombinase-activating gene (RAG)-2–deficient mice.
Since the RAG-2 mutation prevents rearrangement of Ig
genes (32), precursor B cells are developmentally arrested
in the stage of B220
 
low
 
 BP-1
 
2
 
 pro/pre-B–I cells (33, 34).
Analyzing Egr-1 transgenic RAG-2–deficient mice, we
found that pro/pre-B–I cells overcame the RAG-2
 
2
 
/
 
2
 
 in-
duced differentiation block at the stage of B220
 
1
 
 BP-1
 
2
 
pro/pre-B–I cells and differentiated into B220
 
1
 
 BP-1
 
1
 
pre-B–I cells. Comparing B lymphocyte maturation in the
bone marrow of normal transgenic and control animals, we
found that Egr-1 transgenic mice had increased their frac-
tion of mature cells. Because Egr-1–enhanced progression
of developing thymocytes was also found in transgenic
mice overexpressing Egr-1 in T cells (35), we propose that
Egr-1 activity promotes maturation of B and T lympho-
cytes.
 
Materials and Methods
 
Pre-B Cell Cultures.
 
Fetal liver cells of day 15–18 embryos
were removed and plated onto irradiated ST-2 feeder cells in Is-
cove’s medium containing IL-7 and 10% FCS. Cells were cul-
tured as described previously (36). Cells from transgenic lines
were identified by PCR. For further analyses, nonadherent cells
were collected and washed twice in ice-cold PBS. Samples from
wells containing only ST-2 feeder cells were treated in parallel
and served as controls.
 
Mice.
 
The detailed description of the generation of Egr-1
transgenic mice using the BALB/c embryonic stem cell line
BALB/c-I will be described elsewhere. Egr-1 transgenic mice of
the IA7 line were transferred to a special pathogen-free unit by
implanting transgenic one-cell embryos into C57BL/6 foster ani-
mals kept under specific pathogen–free conditions. The IA7 line
was then bred further by mating with wild-type BALB/c mice.
RAG-2
 
2
 
/
 
2
 
 mice expressing transgenic Egr-1 were obtained by
backcrossing female Egr-1 transgenic IA7 mice twice with
C57BL/6 RAG-2
 
2
 
/
 
2
 
 males. Animals were tested by PCR for the
Egr-1 transgene using genomic DNA, 5
 
9
 
-CTTTCGGTTTGGG-
GCTGGACA-3
 
9
 
 and 5
 
9
 
-CGCTGCTGGTGCTGCTGCTGC-
TAT-3
 
9
 
, as transgene-specific primer pair. The RAG-2
 
2
 
/
 
2
 
 phe-
notype was verified by FACS
 
Ò
 
 analysis of peripheral blood cells.
 
RNA Isolation, Northern Blot, and PCR Analysis.
 
RNA was
extracted using the guanidinium isothiocyanate method as de-
scribed (37). For Northern blotting, 10 
 
m
 
g of total RNA was sep-
arated in a 1% agarose gel containing 7% formaldehyde, trans-
ferred onto nylon filters, and fixed by UV cross-linking. Filters
were prehybridized (50% deionized formamide, 5
 
3
 
 SSC, 5
 
3
 
Denhardt’s solution, 50 mM NaH
 
2
 
PO
 
4
 
, pH 7, 10 mM Na
 
4
 
P
 
2
 
O
 
7
 
,
0.1% SDS, 0.1 mg/ml denatured salmon sperm DNA) for 2 h at
42
 
8
 
C. For detection of Egr-1–specific transcripts, [
 
a
 
-
 
32
 
P]dATP-
labeled probes were prepared from a 1.6-kb EcoRI-HindIII frag-
ment from plasmid 533 (a gift from V. Sukhatme) containing the
Egr-1 cDNA by the oligonucleotide priming method (38). The
probe was added to the prehybridization and filters were incu-
bated overnight, washed with 0.2
 
3
 
 SSC, 0.1% SDS at 42
 
8
 
C, and
exposed to X-ray films. Egr-1 expression was analyzed by PCR
using cDNA reverse transcribed from total RNA with Super-
script II (GIBCO BRL, Eggenstein, Germany) and the Egr-1–
specific primers 5
 
9
 
-GCAGATCTCTGACCCGTTCGG-3
 
9
 
 and
5
 
9
 
-CCGAGCGTTTGGCTRGGGATA-3
 
9
 
 as described by T.
Miyazaki (35). PCR was performed using Taq polymerase (MBI
Fermentas, Inc., Amherst, NY) using 1/25 of the cDNA reaction
as template at an annealing temperature of 54
 
8
 
C.
 
Immunoblot Analysis.
 
Bone marrow cells from six femurs
were isolated and resuspended in FACS buffer (0.1% sodium
azide, 3% FCS in PBS). B220-specific biotin-labeled antibody
RA3.3A1 (39) was added and incubated for 30 min on ice. Cells
were washed, magnetic streptavidin-labeled beads (Dynal, Oslo,
Norway) were added, and B cells were isolated. Quality of the
sorting process was verified by flow cytometric analysis. The B
cells were resuspended in 30 
 
m
 
l lysis buffer (1% NP-40, 150 mM
NaCl, 10 mM Tris-HCl, pH 7.0, 0.1 mM PMSF) and incubated
on ice for 10 min. Cell debris was removed by centrifugation (10
min, 4
 
8
 
C, 22,000 
 
g
 
), and the extract was separated by SDS-PAGE
(8%) and transferred onto nitrocellulose membrane (Hybond C
extra; Amersham Pharmacia Biotech, Uppsala, Sweden). Egr-1
was detected using the antiserum C19 (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA) at 25 ng/ml followed by peroxidase-
conjugated goat anti–rabbit IgG F(ab
 
9
 
)
 
2
 
 (Dianova GmbH, Ham-
burg, Germany) at 200 ng/ml. Expression of nur77 was analyzed
using a mouse IgG anti-nur77 mAb (a gift of B. Osborne, Univer-
sity of Massachusetts, Amherst, MA) followed by peroxidase-con-
jugated goat anti–mouse IgG (Southern Biotechnology Associates,
Inc., Birmingham, AL). IgM was detected by a goat anti–mouse
IgM peroxidase-labeled serum (Southern Biotechnology Associ-
ates, Inc.). Signals were visualized using an enhanced chemilumi-
nescence (ECL) detection system (Amersham Pharmacia Biotech).
 
Flow Cytometry.
 
Flow cytometry was carried out as described
previously (40) using the following antibodies: RS3.1-biotin spe-
cific for murine IgM
 
a
 
 (41), 6C3-biotin for BP-1, 7D4-biotin for
IL-2R
 
a
 
 chain, 2B8-biotin for c-kit, S7-biotin for leukosialin,
AMS9.1-biotin for IgD
 
a
 
, RA3-6B2–PE for B220, IM7-biotin for
Pgp-1, 3E2-PE for intercellular adhesion molecule 1 (ICAM-1)
(all from PharMingen Europe, Hamburg, Germany), and biotiny-
lated PB493 (42) to stain immature B lymphocytes. Cells were
counterstained using PE- or APC-conjugated streptavidin (Phar-
Mingen Europe). Unspecific binding to Fc receptors was blocked
by adding unlabeled mouse Fc
 
g
 
R-specific mAb 2.4G2. Dead
cells were excluded by staining with propidium iodide. Using a
FACSCalibur
 
Ò
 
 and CellQuest
 
Ò
 
 software (Becton Dickinson, San
Jose, CA), 3–5 
 
3 
 
10
 
4
 
 cells were acquired according to their for-
ward/side scatter pattern and analyzed. To analyze Egr-1 expres- 
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sion in bone marrow B cell subsets, 3.4 
 
3 
 
10
 
5
 
 pre-B and 7 
 
3 
 
10
 
4
 
immature B cells were isolated from both femurs of a 5-wk-old
BALB/c mouse by cell sorting at 4
 
8
 
C according to their IgM
 
a
 
/
PB493 staining pattern using a FACStar
 
Ò
 
 cell sorter and LYSIS
II
 
Ò
 
 software (Becton Dickinson).
 
Bromodeoxyuridine Treatment and Staining.
 
Bone marrow cells
were labeled with bromodeoxyuridine (BrdU; Sigma, Deisen-
hofen, Germany) starting with a single injection of 1 mg/ml i.p.
BrdU and feeding mice continuously with drinking water con-
taining 1 mg/ml BrdU for 48 h as described (43). During the la-
beling period, the drinking water was protected from light. Si-
multaneous detection of surface staining and BrdU labeling was
done as described (44). After surface marker staining, cells were
resuspended in 500 
 
m
 
l 0.15 M NaCl, 1.2 ml ice-cold 95% ethanol
was added, and the cells were incubated 30 min on ice. Cells
were washed and resuspended in 1 ml fixation buffer (1%
paraformaldehyde and 0.01% Tween in PBS). After incubation
for 30 min at room temperature, the cells were incubated for 30
min in DNase I solution (50 KU DNase I in 4.2 mM MgCl
 
2
 
/
0.15 M NaCl, pH 5). Cells were washed, 10 
 
m
 
l anti-BrdU anti-
body (Becton Dickinson) was added, and the cells were then in-
cubated for 30 min and washed.
 
Electrophoretic Mobility Shift Assays.
 
Gel shift was carried out
using recombinant Egr-1 as described (45) with double-stranded
radiolabeled oligonucleotides from the nur77 and BP-1 promoter
regions carrying putative Egr-1 binding sites (
 
bold
 
): 5
 
9
 
-TTC-
CAAAG
 
TTCCCCCTC
 
AACCCCTC-3
 
9
 
 for BP-1 (position
 
2
 
753 to 
 
2
 
729), 5
 
9
 
-GTCAGTGG
 
CGCCCCCGC
 
CCCTCTC-
CAA-3
 
9
 
 for nur77 (position 
 
2
 
66 to 
 
2
 
50), and 5
 
9
 
-GGATC-
CA
 
GCGGGGGCGAGCGGGGGCG-39 for Egr-1.
Results
Egr-1 Expression in Pre-B and Immature B Cell Precursors.
BCR cross-linking has previously been reported to induce
Egr-1 expression in mature B cells, but not in immature B
lymphocytes or in immature B cell lines (5, 46, 47). We
addressed the question of whether unstimulated pre-B and
immature B cells express Egr-1 by analyzing sorted B cell
subsets from murine bone marrow. Transcription of the
Egr-1 gene was found by PCR in both sIgM2 (pre-B) and
sIgM1 PB4931 immature B cells (Fig. 1 A). Likewise, Egr-1
protein was detected by immunoblotting in sIgM2 pre-B
cells isolated from fetal liver and expanded in culture on
ST-2 stroma cells in the presence of IL-7 (Fig. 1 B). Both
results show transcription of the Egr-1 gene and translation
of Egr-1 mRNA into detectable amounts of protein as
early as the pre-B cell stage before BCR surface expression.
Egr-1 Expression in Transgenic and Normal Mice. These
results suggested that Egr-1 function might also be impor-
tant during early stages of B lymphopoiesis. To test this hy-
pothesis, we generated transgenic mice expressing Egr-1
specifically in B lymphocytes using an Ig heavy chain pro-
moter/enhancer construct. Four different founder mice
showing Egr-1 germline transmission were obtained. By
breeding to BALB/c mice, we established the Egr-1 trans-
genic lines IA7, IB10, IC4, and ID4 (to be published else-
where). At first, we compared Egr-1 expression between
transgenic and BALB/c control mice by Northern and im-
munoblotting (Fig. 2). Spleen cells of the line IA7 ex-
pressed 10-fold more Egr-1 mRNA than the control litter-
mates, whereas the other lines showed Egr-1 expression
levels of about two- to threefold above unstimulated spleen
cells (Fig. 2 A). Since transgenic IC4 mice expressed only
low levels of Egr-1 they were abandoned. Carrying out
most of the experiments with mice from lines IA7, IB10,
and ID4, we found only small variations between these
transgenic lines. Testing Egr-1 protein expression, we
found high levels in purified B2201 bone marrow B cells as
well as in cultivated pre-B cells isolated from fetal liver
(Fig. 2, B and C, respectively).
These results show that transgenic Egr-1 is expressed
during similar stages of B cell maturation, but at far higher
levels than endogenous Egr-1.
Egr-1 Expression Promotes At Least Two Different Stages of
B Cell Development. To examine whether enhanced Egr-1
expression has an effect on early stages of B cell develop-
ment, we backcrossed the IA7 transgenic mice to a RAG-
2–deficient background. The RAG-2 mutation prevents
rearrangement of the Ig genes (32) and therefore blocks B
cell maturation at the pro/pre-B–I cell stage (16, 34).
These cells carry the surface markers c-kit and CD43; ,5–
15% express BP-1 and ,1% express the IL-2Ra chain
(data not shown). Phenotypically, these pro/pre-B–I cells
correspond to fraction B as classified by Hardy et al. (13).
FACSÒ analysis of control and Egr-1 transgenic RAG-2–
deficient mice revealed an unchanged expression pattern
for c-kit and CD43, but a three- to fourfold increase in the
fraction of BP-11 cells, compared with control littermates
(Fig. 3). Phenotypically, these BP-11 c-kit1 CD431 pre-B
lymphocytes are defined as fraction C cells (13), and pro-
gression into this stage normally requires RAG-2 expres-
sion and Ig heavy chain gene rearrangement (16, 34), sug-
gesting that Egr-1 might support the maturation of fraction
B pre-B cells even in the absence of RAG-2 activity. The
reduced cell size of transgenic BP-11 B2201 lymphocytes
as reflected by changes in forward/side scatter (Fig. 3 A, c
Figure 1. Expression of Egr-1
during different stages of B cell
maturation. (A) Egr-1 RNA ex-
pression. Bone marrow cells of a
5-wk-old BALB/c mouse were
stained for B220, PB493, and
IgMa expression. Pro/pre-B cells
(B220low, PB4931, and IgM2)
and immature B cells (B220low,
PB4931, and IgM1) were sorted
and RNA was extracted. Analysis
of Egr-1 transcripts by reverse
transcription PCR was performed
as described by Miyazaki (35). Lane 1 shows expression of Egr-1 in pro/
pre-B cells and lane 2 in immature B cells. Anti-IgM–stimulated spleno-
cytes (lane 3) serve as a positive control. In lane 4, cDNA was omitted
from the PCR. (B) Expression of Egr-1 protein. BALB/c fetal liver B cells
(day 16) were cultivated in the presence of IL-7 on ST-2 stroma cells.
Cellular lysates of 106 cells were examined for Egr-1 expression by immu-
noblotting using the Egr-1–specific antibody C19 and developed with
horseradish peroxidase–coupled goat anti–rabbit IgG. In cultivated pre-B
cells, Egr-1 protein expression is easily detected (lane 2). As a negative
control an equal amount of ST-2 feeder cells was loaded in lane 1.2218 Egr-1 Advances B Cell Development
and d) also supports the Egr-1–induced progression of B
cell development. Since we did not detect cell surface
markers characteristic for pre-B–II/fraction D cells, i.e., IL-
2Ra and high levels of heat-stable antigen, the expression
of the Egr-1 transgene seems to promote the transition of
pre-B–I cells from fraction B to fraction C but not further.
These results indicated that Egr-1 expression might also
change maturation of later stage bone marrow B cell sub-
sets. According to the expression pattern of B220 and IgM,
three main subsets corresponding to three consecutive
stages of maturation can be distinguished: IgM2 B220low
pre-B cells, B220low IgM1 IgD2 immature B cells, and fi-
nally the B220high IgM1 IgD1 mature B cells (16, 48). The
proportion of mature B cells in the bone marrow increases
with the age of the animal. Therefore, mice at 4 wk of age
have fewer mature B cells than older animals. Comparing
23 control littermates with 23 IA7 transgenic mice between
4 and 40 wk of age, we found in general fewer immature
and more mature B cells in the IA7 bone marrow than in
age-matched controls (Fig. 4). These results suggest that
Egr-1 also promotes the differentiation of immature B cells
into mature B cells.
Normal Proliferation of B Cells in Egr-1 Transgenic Mice.
The enlarged population of BP-11 pre-B cells in transgenic
RAG-2–deficient mice and the higher percentage of ma-
ture cells in transgenic RAG-21 animals could result from
an increased proliferative potential of B cell precursors. Be-
cause dividing B lymphocytes can be traced by incorpora-
tion of the nucleotide analogue BrdU (49), we compared
the proportion of BrdU1 cells in the pre-B, immature B,
and mature B cell subsets between control littermates and
transgenic mice after 2 d of in vivo labeling. The similar
percentages of BrdU1 cells in all B cell subsets of both
groups of mice suggest that the expression of transgenic
Egr-1 does not change the proliferative potential of B cells
(Fig. 5).
Regulation of Downstream Genes. The increased matura-
tion of transgenic B cells would be expected to correlate
with changes in the expression of genes controlled directly
or indirectly by Egr-1. Using a panel of antibodies, we
screened transgenic bone marrow B cells for alterations in
the expression pattern of B cell–specific surface markers by
flow cytometry. Changes were not observed except for a
slight increase in the percentage of BP-11 cells and in BP-1
expression levels in all transgenic lines (Fig. 6 A). As dis-
cussed above, the proportion of BP-11 cells might relate to
the Egr-1–enhanced transition of fraction B pre-B cells
into the fraction C stage, but it would not explain higher
BP-1 surface levels. Therefore, we speculated that Egr-1
might regulate the transcription of the BP-1 gene and
screened the BP-1 promoter for potential Egr-1 binding
Figure 2. Expression of transgenic Egr-1. (A) Comparison of Egr-1
mRNA levels in BALB/c and Egr-1 transgenic spleen cells. RNA was
extracted from splenocytes, and Northern blot analysis was performed
using a probe specific for endogenous and recombinant Egr-1
mRNA. Because the endogenous and transgenic Egr-1 mRNA spe-
cies migrate with different electrophoretic mobilities, they are easily
identified on Northern blots (data not shown). To standardize for the
amounts of mRNA, filters were rehybridized with a GAPDH-specific
probe. The relative intensity of the Egr-1 expression in BALB/c and
in four transgenic lines IA7, IB10, IC4, and ID4 was determined using
a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). (B) Expres-
sion of Egr-1 protein in B cells of the bone marrow. B2201 B cells
were purified from the bone marrow of three BALB/c and three ID4
transgenic mice using streptavidin-loaded magnetic beads and the
B220-specific, biotinylated antibody RA3.3A1. Whole cell lysates
with equal amounts of protein were analyzed for Egr-1 expression by
immunoblotting using the Egr-1–specific antibody C-19 (a). Lane 1
shows Egr-1 expression in BALB/c bone marrow cells, lane 2 in ID4
mice. In parallel, samples were stained with a horseradish peroxidase–conjugated goat anti–mouse IgM antibody to standardize for the different amounts
of protein loaded per lane (b). (C) Increased expression of Egr-1 protein in transgenic pre-B cells. Pre-B cell cultures and immunoblots were performed
as described for Fig. 1 B. Transgenic pre-B cells (IA7, lane 1) express higher levels of Egr-1 than an equal amount of wild-type BALB/c pre-B cells (lane
2). Egr-1 protein is undetectable in whole cell lysates of corresponding numbers of ST-2 feeder cells (lane 3).
Figure 3. Egr-1 induces development of BP-11 B220low pre-B cells.
Bone marrow cells of IA7 transgenic mice with a RAG-2 background
and control littermates were stained with BP-1– and B220-specific anti-
bodies and analyzed by flow cytometry. Dead cells were excluded by gat-
ing for propidium iodide–negative cells, and 5 3 104 cells were acquired
according to their forward/side scatter (FSC, SSC) profile. As shown for
one individual example in A, IA7 mice (b) have about three times more
BP-11 cells than control littermates (a). Changes in the forward/side scat-
ter pattern document that most of the B2201 BP-11 cells (74% small cells,
d) are smaller than the majority of BP-12 cells (37% small and 54% large
cells, c). B compiles the BP-1 staining pattern for six RAG-2–deficient
IA7 mice and six control littermates.2219 Dinkel et al.
sites. Finding a (59-GAGGGGGAA) sequence z1.6 kb up-
stream of the mRNA start (50) resembling an Egr-1 bind-
ing site (59-GCGGGGGCG), we analyzed by an electro-
phoretic mobility shift assay (EMSA) if recombinant Egr-1
binds to an oligonucleotide containing the putative Egr-1
recognition site from the BP-1 promoter. As shown in Fig.
6 C, labeled oligonucleotides containing a cognate Egr-1
binding site (lane 1) or the binding site from the BP-1 pro-
moter (lane 15) produced a shifted DNA–protein complex
with identical electrophoretic mobility. Their intensities
were reduced only by adding an excess of unlabeled oligo-
nucleotides with an Egr-1 binding site but not by compet-
ing with an Sp-1 binding site (lanes 2–5 and 16–19, respec-
tively). Likewise, only the addition of Egr-1– but not of
Sp-1–specific antibodies retarded the migration of the com-
plex (lanes 6 and 7, 20 and 21). Therefore, the forced ex-
pression of Egr-1 in transgenic B cells may not only help
pre-B cells to proceed from fraction B into fraction C but
may also enhance the expression of BP-1, which is nor-
mally upregulated during this transition.
The nur77 gene (also called NGFI-B [3] or N10 [51])
encoding an orphan nuclear receptor represents one of the
transcription factors found to be induced by Egr-1 (52).
Analyzing nur77 expression in purified B2201 bone mar-
row cells of transgenic (ID4) and control littermates by
Western blotting, we found nur77 to be expressed only by
transgenic but not by control B cells (Fig. 6 B). Since up-
regulated nur77 expression was not found in cultivated
transgenic sIg2 pre-B cells (data not shown), the induction
of the nur77 gene seems to be confined to pre-B–II or
sIgM1 bone marrow cells. To analyze if Egr-1 could di-
rectly induce nur77 transcription, we tested by EMSA the
binding of recombinant Egr-1 to an oligonucleotide of the
nur77 promoter (position 274 to 250) containing a cog-
nate Egr-1 binding site. As shown in Fig. 6 C, binding of
recombinant Egr-1 produced a DNA–protein complex
(lane  8). The specificity of Egr-1 binding was demonstrated
by a competition assay using an excess of an oligonucle-
otide carrying an Egr-1 binding site (lanes 11 and 12) and
by the decreased mobility of the complex upon the addi-
tion of an Egr-1–specific antibody (lane 13).
Since it was shown recently that nur77 activity is in-
volved in the induction of apoptosis during negative selec-
tion of thymocytes (53–56) and in the upregulation of
CD95L expression (57), we looked for enhanced CD95L
expression in Egr-1 transgenic mice compared with control
littermates. In contrast to the results reported for nur77–
expressing T cells, we did not find increased CD95L ex-
pression in Egr-1 transgenic B cells (data not shown).
In response to BCR-derived signals, Egr-1 is thought to
modulate the expression pattern of downstream genes that
promote further activation and differentiation of B lym-
phocytes. Using variants of the B cell line WEHI-231, it
was shown that Egr-1 induces the expression of CD44 and
of intracellular adhesion molecule 1 (ICAM-1 [58, 59]).
Therefore, we tested the expression pattern of both surface
markers in our transgenic mice, but did not detect differ-
ences when compared with BALB/c controls (data not
shown).
Discussion
Egr-1 Accelerates B Cell Maturation. Mature B cells re-
spond to signals resulting from antigen receptor engage-
ment by immediately inducing Egr-1 transcription (5), but
the role of Egr-1 in earlier stages of B cell development has
Figure 4. Higher frequency of
mature and lower frequency of
immature bone marrow B cells in
Egr-1 transgenic mice. (A) Com-
pares the differences between the
B220low IgM1 (immature) and
B220high IgM1 ( mature) B cell
subsets of control littermates and
transgenic mice. Bone marrow
cells of 4–40-wk-old BALB/c lit-
termates (n  5  23) and of IA7
transgenic mice (n  5  23) were
stained for IgM (RS3.1) and B220 (RA3-6B2) and analyzed by flow cytometry after acquisition of 3 3 104 cells gated according to their forward/side
scatter profile. The first diagram (a) compares the changes in the percentage of immature IgM1 B220low cells between age-matched BALB/c littermates
(open circles) and IA7 mice (filled circles) over a period of 36 wk. P values ,0.05 corresponding to the individual time points indicate statistically significant
differences between transgenic and control mice. The second diagram (b) shows the increase in the percentage of mature IgM1 B220high cells in older
mice. Although transgenic IA7 mice tend to have more mature bone marrow B cells, they do not show the statistically significant differences seen for the
immature B cells. (B) Two individual examples of a BALB/c littermate (a) and an IA7 transgenic mouse (b) at 18 wk. The numbers indicate the percent-
age of B2201 cells in each subset. Similar analyses of bone marrow B cells from the IB10 and ID4 transgenic mice showed almost identical results.
Figure 5. Similar prolifera-
tion of IA7 and BALB/c bone
marrow B cell subsets. To deter-
mine the fraction of cycling bone
marrow B cells, nine BALB/c
and eight IA7 littermates were
fed with BrdU for 2 d. Bone
marrow cells were analyzed flow
cytometrically by acquiring 3 3
104 cells stained for B220 and
IgM as described in the legend to
Fig. 2, and after permeabilization
with an FITC-labeled anti-BrdU
antibody. In both groups of mice pre-B (IgM2 B220low), immature (IgM1
B220low) BALB/c, and mature (IgM1/low B220high) bone marrow B cells
incorporated similar amounts of BrdU, indicating comparable prolifera-
tion rates. Similar results were obtained when we used ID4 instead of IA7
transgenic mice.2220 Egr-1 Advances B Cell Development
not been defined. The different stages and the order of B
cell development are well characterized, allowing the pre-
cise typing of bone marrow B cells according to the expres-
sion of characteristic cell surface markers, the rearrange-
ment of Ig genes, and the proliferative and differentiation
potential of B cell precursors (13, 14, 16, 60, 61). By ana-
lyzing Egr-1 expression in bone marrow–derived B lym-
phocyte subsets and by testing Egr-1 expression in culti-
vated, fetal liver–derived pre-B cells, we have shown that
Egr-1 is also expressed in pre-B cells lacking sIgM as well as
in immature sIgM1 B cells in the absence of sIgM-induced
signals. These observations suggest that Egr-1 might also
have a regulatory function in pre-B cell development. By
studying transgenic mice overexpressing Egr-1 from the
pre-B stage on, we have found higher proportions of ma-
ture B cells and fewer immature B cells in transgenic ani-
mals than in control littermates. To identify if early stages
of B lymphopoiesis are sensitive to Egr-1 activity, we ar-
rested B cell development at the stage of pro/pre-B–I cells
by backcrossing the Egr-1 transgenic line IA7 to mice defi-
cient in RAG-2. Since the null mutation in the RAG-2
gene prevents rearrangement of Ig genes (32), B cell pre-
cursors do not receive stimulating signals required for
developmental progression beyond the stage of B220low
CD431 BP-12 pro/pre-B cells (16, 62), also defined as
fraction B (13). Comparing the phenotype of bone marrow
pro/pre-B cells from transgenic and control mice, we
found a three- to fourfold increased population of BP-11
pre-B cells in Egr-1 transgenic mice. Since the transcrip-
tion activation function of Egr-1 seems to enhance BP-1
expression in more mature B cell subsets, the increase in
BP-11 pre-B cells could also reflect the induction of BP-1
expression only and not Egr-1–induced differentiation.
However, this seems to be less likely because transgenic
BP-11 cells were found to be smaller than BP-12 cells,
consistent with further maturation. Therefore, these results
suggest that forced expression of Egr-1 in BP-12 pro/pre-B
cells induces progression into the stage of BP-11 pre-B
cells (fraction C). Since these cells failed to upregulate the
IL-2Ra chain and heat-stable antigen, two markers charac-
teristic for pre-B–II cells (fraction C9 and D [13, 16]),
overexpression of Egr-1 in pro/pre-B–I cells seems to be
sufficient to induce differentiation to fraction C, but not to
more mature stages of B lymphopoiesis.
Progression of pro/pre-B cells developmentally arrested
by a mutation in the RAG-2 gene into more mature pre-B
cell stages is also induced by in vivo cross-linking of the Ig-
a/Ig-b heterodimer using Ig-b–specific mAbs (63). Under
those conditions, anti–Ig-b–treated pro/pre-B–I cells be-
come smaller in size and acquire IL-2Ra expression in
addition to BP-1. Since they also downregulate c-kit
(CD117) and CD43, they are considered as small pre-B–II
cells. In the same report, it was shown that Ig-b cross-link-
ing stimulates tyrosine phosphorylation of several substrate
Figure 6. Expression of downstream
genes depending on Egr-1 activity. (A) Up-
regulated BP-1 expression in transgenic
mice. Bone marrow cells from a BALB/c
control littermate and an IA7 mouse were
analyzed flow cytometrically by acquiring
3 3 104 live cells stained for B220, IgM,
and BP-1. The dot plots are gated B2201
cells and illustrate increased levels and a
higher percentage of BP-1 staining in both
IgM2 and IgM1 subsets. IB10 and ID4 mice
showed very similar changes in BP-1 ex-
pression. (B) Induction of nur77 in trans-
genic bone marrow B cells. Using ID4 and
BALB/c mice with comparable percentages
of mature bone marrow B cells, B2201 cells
were purified from the bone marrow as de-
scribed in the legend to Fig. 2. In the
BALB/c sample, protein extracts from 3.3 3
106 B220low and 1.3 3 105 B220high cells (as
determined by FACSÒ analysis) were
loaded; for the ID4 sample, the respective
amounts were 3 3 106 B220low and 2 3 105
B220high cells. Nur77 expression was de-
tected by Western blotting using a nur77-
specific antibody. The amount of protein
loaded per lane was controlled by reprobing
the blots with a goat anti–mouse IgM anti-
body. The staining shows elevated nur77 expression in ID4. Size markers (in kD) as indicated were run in parallel to the samples. (C) Binding of recom-
binant Egr-1 to sequences present in the BP-1 and nur77 promoters. Recombinant Egr-1 was incubated with radioactively labeled oligonucleotides car-
rying a cognate Egr-1 binding site (lanes 1–7, Egr-1), with an oligonucleotide from the nur77 promoter (lanes 8–14, nur77), or with an oligonucleotide
from the BP-1 promoter (lanes 15–21, BP-1) and analyzed by EMSA as described previously (reference 45). The sequences of the respective Egr-1 bind-
ing sites are shown (top). Specific binding was proven first by competing either with an excess of an unlabeled oligonucleotide carrying a cognate Egr-1
binding site (lanes 4, 5; 11, 12; 18, 19) or by using an oligonucleotide with an Sp-1 site (lanes 2, 3; 9, 10; 16, 17), and second by inducing a “supershift”
by adding the Egr-1–specific antibody C19 to the binding reaction (lanes 6, 13, and 20). Replacing the Egr-1–specific antibody with an Sp-1–specific an-
tibody had no effect on the migration of the DNA–Egr-1 complex (lanes 7, 14, and 21).2221 Dinkel et al.
proteins, including Ig-a, Syk, and Vav, and the activation
of mitogen-activated protein kinase extracellular signal–
regulated kinase (ERK)1. Based on these results, Nagata et
al. (63) proposed that the signal cascade initiated by Ig-b
activation evokes differentiation signals similar to those de-
livered by the pre-BCR in normal B cell development. For
mature B cells it is known that BCR engagement upregu-
lates Egr-1 transcription through a signal cascade including
p21/ras and mitogen-activated protein kinase (ERK [10,
64]), and for other cell types it has been shown that ERK
activation induces Egr-1 transcription (65). Since RAG-2–
deficient pro/pre-B–I cells overexpressing Egr-1 do not
reach the same developmental stage as anti–Ig-b–stimulated
cells, it seems likely that Egr-1 activity substitutes only part
of the differentiation signal originating from the pre-BCR.
Analyzing later stages of B cell development in RAG-
21/1 Egr-1 transgenic mice, we observed lower propor-
tions of immature and increased proportions of mature
bone marrow B cells compared with their wild-type litter-
mates, whereas there was no increased proliferation of
transgenic pre-B or immature B cells detectable. These
findings are consistent with the current model of the devel-
opment from immature to mature B cells (66, 67). Imma-
ture B cells leave the bone marrow and enter the spleen
where about half of them reach the mature stage (42). Ma-
ture bone marrow B cells are thought to be part of the re-
circulating pool. This would suggest that Egr-1 influences
this migration at one or several steps.
Egr-1 expression was also found in CD42CD82 double
negative thymocytes by Miyazaki (35). Overexpression of
transgenic Egr-1 in a RAG-2–deficient background al-
lowed thymocytes to bypass the RAG-2–dependent block
at the IL-2R1 Pgp-12 double negative stage and develop
into immature CD8 single-positive cells, but not further to
the CD41CD81 double-positive cell stage. In cortical
CD41CD81 thymocytes, Egr-1 expression was reported
by Shao et al. (68) to be dependent on TCR engagement,
suggesting that high level expression of Egr-1 in the thy-
mus might be a consequence of thymocyte selection. The
high coincidence of Egr-1 expression in analogous B and T
cell precursor subsets and the increased differentiation of
pro/pre-B–I cells and thymocytes in Egr-1 transgenic mice
suggest that Egr-1 activity regulates similar functions in
both types of lymphocytes.
Downstream Target Genes. Searching for potential down-
stream target genes responding to Egr-1, we found in-
creased expression of the nuclear orphan receptor nur77 in
bone marrow B cells from transgenic mice but not in culti-
vated transgenic pro/pre-B–I cells. Since we also could
demonstrate binding of recombinant Egr-1 to a cognate
Egr-1 binding site present in the nur77 promoter, it seems
likely that Egr-1 directly induces nur77 expression in B
lymphocytes before the mature B cell stage. It was reported
that nur77 activity is involved in the regulation of thymo-
cyte apoptosis (53, 54) by inducing CD95L expression
(57). However, in the Egr-1 transgenic mice, we could de-
tect neither upregulation of CD95L expression by bone
marrow B cells nor an increased frequency of apoptotic
cells (Warnatz, K., unpublished results). On the other
hand, cellular responses other than apoptosis may be linked
to nur77 function, since it is also induced upon antigen re-
ceptor ligation in B and T cells during proliferative re-
sponses (52, 69). Besides nur77 promoter, we also found
enhanced expression of BP-1 in pre-B–II and in IgM1
bone marrow cells. Similar to the nur77, we could also
demonstrate binding of recombinant Egr-1 to a sequence
from the BP-1 promoter resembling an Egr-1 binding site.
Therefore, it seems that Egr-1 activity promotes not only
development to the stage of BP-11 cells (fraction C), but
also an increased surface expression of BP-1 on BP-11 B
cells. Although it is known that BP-1 acts as an aminopep-
tidase catalyzing the hydrolysis of acidic amino acid resi-
dues from the NH2 termini of proteins (70), its role in B
lymphopoiesis remains to be clarified (71, 72).
Conclusions. Here we provide evidence that Egr-1 sup-
ports at least two distinct steps of B cell maturation, the
progression into the pre-B and into the mature B cell stage.
Since Egr-1 activity is also sufficient to promote the devel-
opment of double negative thymocytes into immature sin-
gle-positive CD8low cells (35), as well as macrophage in
vitro differentiation (73, 74), this transcription factor seems
to play an important role in the differentiation of three ma-
jor hematopoietic cell types.
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